Account

Sign in to access your account and subscription

Federal Circuit Applies Bilski Standard in Classen

The Federal Circuit's October 2008 decision in <i>In re Bilski</i> created uncertain implications for biotechnology regarding the applicable standard for patent eligibility under 35 U.S.C. &sect;101. In its recent one-paragraph opinion in <i>Classen Immunotherapies v. Biogen IDEC</i>, the Federal Circuit left many issues unexplained, but it did make one thing clear: The <i>Bilski</i> standard, now being applied in the area of biomedical technology, poses a significant threat to the viability of patents claiming diagnostic methods.

15 minute read February 26, 2009 at 02:52 PM
By
Warren D. Woessner and Tania A. Shapiro-Barr
Federal Circuit Applies Bilski Standard in Classen

The Federal Circuit's October 2008 decision in In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en banc), created uncertain implications for biotechnology regarding the applicable standard for patent eligibility under 35 U.S.C. '101.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

The combination of increasing operating costs and uncertain government reimbursement funding continues to place health care providers under financial pressure, and in many cases, financial distress. Given the importance of Medicare/Medicaid funding of claims under provider agreements with the federal government, how courts interpret and apply the interplay between the Bankruptcy Code and Medicare Program Act determines the disposition of hundreds of millions of dollars of claims for reimbursement that support the health care system.

April 30, 2026

As AI becomes embedded in everyday business and legal operations, organizations are confronting a new expectation: simply disclosing AI use is no longer enough. A critical shift is taking place in the legal industry: transparency is no longer just about disclosure; it’s about comprehension.

April 30, 2026